Comparison of preoperative serum neopterin, periostin, indoleamine 2,3‐dioxygenase, YKL‐40, and tenascin‐C levels with current tumor markers for early‐stage endometrial cancer

Songul Unuvar,Rauf Melekoglu,Nese B. Turkmen,Ercan Yilmaz,Seyma Yasar,Hande Yuce
DOI: https://doi.org/10.1002/ijgo.13666
2021-03-24
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To compare the predictive value of serum levels of neopterin, periostin, YKL‐40, tenascin‐C (TNC), and indoleamine 2,3‐dioxygenase (IDO) with current tumor markers for the primary diagnosis of early‐stage endometrial cancer.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A prospective cross‐sectional study was conducted between January 2020 and November 2020. A total of 59 patients (38 women newly diagnosed with early‐stage endometrial cancer [study group] and 21 women with benign endometrial pathologies [control group]) were enrolled. Blood samples were collected prior to surgery and underwent immunoassay analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Carcinoembryonic antigen (CEA), periostin, and IDO levels were significantly higher in the study group than the control group (<i>P </i>= 0.008, <i>P </i>= 0.034, and <i>P</i> = 0.003, respectively). Receiver operating characteristic curve analysis revealed that IDO, periostin, and CEA were good predictors of early‐stage endometrial cancer (AUC=0.733, 95% CI, 0.602–0.840, <i>P </i>&lt; 0.002; AUC=0.668, 95% CI, 0.533–0.785, <i>P</i> = 0.018; and AUC=0.709, 95% CI, 0.576–0.820, <i>P</i> = 0.002, respectively). Correlation analysis revealed no significant correlation of any biomarker with age or body mass index in either the control or study group. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Serum CEA, periostin, and IDO levels were significantly higher in women with endometrial cancer than in those without cancer. These results may help identify new markers for diagnosing endometrial cancer.</p></section>
obstetrics & gynecology
What problem does this paper attempt to address?